Clinical trial · Observational
LUTATHERA Injection General Use Result Survey
LUTATHERA Injection General Use Result Survey (Somatostatin Receptor-positive Neuroendocrine Tumor, CAAA601A11401)
NCT05844332CI-TRIAL-00099440completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study was a multicenter observational study with a central registration system and all-case surveillance system without a control group.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Somatostatin Receptor-positive Neuroendocrine Tumor | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| LUTATHERA | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- LUTATHERA
- description
- patients treated with LUTATHERA Injection
- interventionNames
- Other: LUTATHERA
Primary outcomes (1)
- measure
- Proportion of patients with Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises
- timeFrame
- Until 40 weeks after the date of the last dose (64 weeks if 4 doses are administered 8 weeks apart).
- description
- To evaluate the safety about Renal dysfunction, Myelosuppression, Myelodysplastic syndrome/acute myeloid leukaemia and Hormone release induced crises after administration of this drug in a real world setting
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * All patients treated with this drug for the following indications during a certain post-marketing period * Indication: Somatostatin receptor-positive neuroendocrine tumor Patients who started to receive this drug before the contract for this study will also be included in the study population and it will be allowed to register them after the contract so that all patients who receive this drug will be included in this study. Patients treated with this drug for off-label indication will also be included in this study to register all patients received this drug. Exclusion Criteria: * Not applicable
References
Publications (0)
Data not yet available
No reference posted for this study.